Safety of sofosbuvir-based regimens after liver transplantation: longitudinal assessment of renal function in the prospective ANRS CO23 CUPILT study.
R AntyGuillaume FavreA CoillyE RossignolP Houssel-DebryC DuvouxVictor De LedinghenV Di MartinoV LeroyS RadenneN KamarV CanvaL D'AlterocheF DurandJérôme DumortierP LebrayC BeschA TranC M CanivetD Botta-FridlundH MontialouxC MorenoF ContiC SilvainP PerréF HabersetzerA AbergelM Debette-GratienS DharancyV L M EsnaultC Fougerou-LeurentC CagnotA DialloA VeislingerH DanjouD SamuelGeorges Philippe PageauxJ-C Duclos-Valléenull nullPublished in: Alimentary pharmacology & therapeutics (2018)
The eGFR varies during treatment and gives a confusing picture of the renal safety of sofosbuvir-based regimens. In contrast, longitudinal assessment of the eGFR shows a rising trajectory over longer time, meaning that these therapies are safe for the kidneys in our cohort of liver transplant recipients.